About Intellikine
Intellikine is a Healthcare company based in San Diego (United States) founded in 2007, and was acquired by Takeda in December 2011. PI3KmTOR pathway inhibitors for cancer treatment were developed. Intellikine has raised $67.5 million across 3 funding rounds from investors including Takeda Pharmaceuticals, Biogen and Abingworth. Its focus areas include Life Sciences, Oncology, Drugs and Pan Cancer. Its legal entity is Intellikine Inc. Its competitors include TScan Therapeutics, GigaGen and Shattuck Labs; 3 of its 3 listed competitors have raised funding.
Company details
Intellikine was founded in 2007 in San Diego, United States, as a clinical-stage biotechnology company. Operations centered on the discovery and development of orally available small molecule drugs targeting the PI3KmTOR pathway, which is linked to cancer and other diseases. A structure-based approach was employed to advance a pipeline of drug candidates. The company was acquired by Takeda Pharmaceuticals in December 2011.
- Headquarters San Diego, United States
- Stage Acquired
- SectorsHealthcare
- Website intellikine.com
- Social LinkedIn
- Acquired by Takeda (Dec 2011)
- Legal Name Intellikine Inc
- Total Equity Funding$67.5M (USD)
in 3 rounds
- Latest Funding Round$4M (USD), Series C
Oct 2011
- InvestorsTakeda Pharmaceuticals
& 7 more
- Acquired byTakeda
(Dec 2011)
Funding Insights of Intellikine
Intellikine has successfully raised a total of $67.5M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $4 million completed in October 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $67.5M
- Total Rounds 3
- Last Round Series C — $4M
- First Round $12.5M
(Sep 2007)
- Investors Count 7
All 3 funding rounds of Intellikine with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2011 | $4M | Series C | – | – | – |
| Jul 2009 | $51M | Series C | – | USVP, Novartis Venture Fund | – |
| Sep 2007 | $12.5M | Series A | – | – |
8 investors in total: 8 institutional.
Investors in Intellikine
Intellikine has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Takeda Pharmaceuticals, Biogen and Abingworth.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
VC firm that focuses on early stage investments in the US | usvp.com | Menlo Park, United States | ||
Investments are made in innovative life science companies globally. | nvfund.com | Basel, Switzerland | ||
Biotech funding, drug development support, and investment in life sciences. | sofinnova.com | |||
Early stage venture capital firm investing in US | 1973 | abingworth.com | London, United Kingdom | |
| cmea.com | ||||
Investment banking advisory services | 1994 | fgi.co.jp | Shinagawa, Japan | |
Therapies for neurodegenerative and immunology disorders are developed. | 1978 | biogen.com | Cambridge, United States | |
Takeda Pharmaceuticals is engaged in developing innovative medicines globally. | 1781 | takeda.com | Tokyo, Japan |
Investor details for Intellikine
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Intellikine
4 dated milestones of Intellikine across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Intellikine is founded.
- Funding First funding round of $12.5M.
- Funding Latest funding round, Series C, of $4.0M.
- Exit Acquired by Takeda.
Competitors of Intellikine
Intellikine has 3 listed competitors in our database, 3 of them funded. They include TScan Therapeutics, GigaGen and Shattuck Labs.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| tscan.com | 1995 | Boston, United States | $158.3M | 154 | T cell-based treatments for immunological and oncological disorders are developed. | |
| gigagen.com | 2011 | San Francisco, United States | $36.13M | 36 | T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms. | |
| shattucklabs.com | 2016 | Austin, United States | $165.4M | 89 | An immunotherapy platform for oncology and other diseases is developed. |
Detailed competitors of Intellikine
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Oncology
3 companies that operate in the same segment as Intellikine (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Intellikine
Intellikine was founded in 2007.
Intellikine is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Intellikine is a funded company, having raised a total of $67.5M across 3 funding rounds to date. The company's 1st funding round was a Series A of $12.5M, raised on Sep 2007.
Intellikine was founded in 2007 in San Diego, United States, as a clinical-stage biotechnology company. Operations centered on the discovery and development of orally available small molecule drugs targeting the PI3KmTOR pathway, which is linked to cancer and other diseases. A structure-based approach was employed to advance a pipeline of drug candidates. The company was acquired by Takeda Pharmaceuticals in December 2011.
Intellikine's top competitors include GigaGen, Shattuck Labs and TScan Therapeutics.
Intellikine has 8 investors. Key investors include Takeda Pharmaceuticals, Biogen, Abingworth, FinTech Global Incorporated, and USVP.
Intellikine operates through Intellikine Inc.
Yes. Intellikine was acquired by Takeda in December 2011.